The researchers will combine genomic analysis with environmental and mobile device data from 1,200 participants to try to better understand the disease.
The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.
Linguamatics' I2E natural language processing engine helps Sanofi match HLA alleles with multiple sclerosis and associated drug treatments.
The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
Berg will use its Interrogative Biology platform in order to assess potential biomarkers of seasonal influenza vaccination outcomes.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.